MRKR - Marker Therapeutics GAAP EPS of -$0.34 revenue of $257.61M November, 10 2023 11:12 AM Marker Therapeutics Inc. 2023-11-10 11:12:12 ET More on Marker Therapeutics Marker gains as lymphoma therapy leads to complete remission Financial information for Marker Therapeutics For further details see: Marker Therapeutics GAAP EPS of -$0.34, revenue of $257.61M